Literature DB >> 22215357

Practical considerations for optimal transdermal drug delivery.

Cheryl Durand1, Abdullah Alhammad, Kristine C Willett.   

Abstract

PURPOSE: The properties of various transdermal drug delivery system (TDDS) products are reviewed, with safety recommendations and guidance on addressing questions frequently posed by patients and caregivers.
SUMMARY: Drug delivery via a TDDS can offer many advantages over other methods of administration, but those benefits can be compromised by improper use or alteration of medication patches or a lack of awareness of the properties of different patch types (reservoir, matrix, drug-in-adhesive). To assess current TDDS technologies and recommended practices for safe and effective use of medication patches, a literature search for articles on commonly used TDDS products available in the United States was conducted; supplemental information was obtained from package inserts and through direct communication with manufacturers. In addition to recommendations on the site and duration of TDDS application and proper patch disposal, clinicians must consider (1) potential problems with cutting patches as a method of dosage adjustment, (2) safety concerns related to the electric conductivity of metal-containing patches, (3) appropriate strategies for managing patch adhesion failures, and (4) the advisability of writing on patches for medication safety or compliance reasons. Clinicians should also be prepared to counsel patients about TDDS-specific recommendations on the avoidance of sunlight and other external heat sources during the use of a medication patch.
CONCLUSION: Practical considerations related to transdermal drug delivery include the appropriateness of cutting patches, the implications of their containing metallic components, and whether they may be covered with tape or written on. Manufacturers of patches provide some useful information on these topics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22215357     DOI: 10.2146/ajhp110158

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  9 in total

Review 1.  Transdermal patches: history, development and pharmacology.

Authors:  Michael N Pastore; Yogeshvar N Kalia; Michael Horstmann; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2015-03-18       Impact factor: 8.739

2.  Development and evaluation of α-asarone transdermal patches based on hot-melt pressure-sensitive adhesives.

Authors:  Zhenwei Yu; Yi Liang; Wenquan Liang
Journal:  AAPS PharmSciTech       Date:  2013-01-10       Impact factor: 3.246

3.  The Incidence of Severe Diarrhea with Transdermal Fentanyl Patch: An Uncommon Event.

Authors:  Karim Hemati; Poupak Rahim Zadeh
Journal:  J Clin Diagn Res       Date:  2015-06-01

Review 4.  Nanoparticle-Enabled Transdermal Drug Delivery Systems for Enhanced Dose Control and Tissue Targeting.

Authors:  Brian C Palmer; Lisa A DeLouise
Journal:  Molecules       Date:  2016-12-15       Impact factor: 4.411

Review 5.  Expert consensus of the Chinese Association for the Study of Pain on pain treatment with the transdermal patch.

Authors:  Ke Ma; Wei Jiang; Yun-Xia Wang; Lin Wang; Yan Lv; Jin-Feng Liu; Rong-Guo Liu; Hui Liu; Li-Zu Xiao; Dong-Ping Du; Li-Juan Lu; Xiao-Qiu Yang; Ling-Jie Xia; Dong Huang; Zhi-Jian Fu; Bao-Gan Peng; Yan-Qing Liu
Journal:  World J Clin Cases       Date:  2021-03-26       Impact factor: 1.337

6.  Therapeutic intradermal delivery of tumor necrosis factor-alpha antibodies using tip-loaded dissolvable microneedle arrays.

Authors:  Emrullah Korkmaz; Emily E Friedrich; Mohamed H Ramadan; Geza Erdos; Alicia R Mathers; O Burak Ozdoganlar; Newell R Washburn; Louis D Falo
Journal:  Acta Biomater       Date:  2015-06-18       Impact factor: 8.947

Review 7.  Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS).

Authors:  Robert L Findling; Steven Dinh
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

8.  Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system.

Authors:  Henrik Lövborg; Mikael Holmlund; Staffan Hägg
Journal:  BMC Pharmacol Toxicol       Date:  2014-06-09       Impact factor: 2.483

Review 9.  Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain.

Authors:  Tracy L Skaer
Journal:  J Pain Res       Date:  2014-08-19       Impact factor: 3.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.